Zoetis Inc (ZTS)

Currency in USD
151.02
+0.27(+0.18%)
Closed·
After Hours
151.30+0.29(+0.19%)
·
ZTS Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected in 6 days
Fair Value
Day's Range
148.54151.04
52 wk Range
139.70200.33
Key Statistics
Prev. Close
150.75
Open
150.02
Day's Range
148.54-151.04
52 wk Range
139.7-200.33
Volume
2.7M
Average Volume (3m)
3.08M
1-Year Change
-16.18%
Book Value / Share
10.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZTS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
195.55
Upside
+29.49%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 12 consecutive years

Zoetis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Zoetis Inc Company Profile

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.

Employees
13800

Zoetis Inc SWOT Analysis


Market Leadership
Zoetis maintains dominance in animal health, with a robust portfolio spanning companion animal and livestock sectors, despite increasing competition
Financial Resilience
Analysts project continued growth, with Q3 2024 organic revenue expected to rise 9.2%. Price targets range from $225 to $242, reflecting positive outlook
Product Innovation
Explore Zoetis's key growth drivers, including Librela for canine osteoarthritis and Apoquel for dermatology, alongside a promising pipeline in oncology and cardiology
Future Prospects
Delve into Zoetis's strategies for tapping untapped markets in animal anti-depressants and pain management, while navigating challenges like foreign exchange impacts
Read full SWOT analysis

Zoetis Inc Earnings Call Summary for Q1/2025

  • Zoetis surpassed Q1 2025 expectations with EPS of $1.48 and revenue of $2.22B, showing 9% organic operational growth
  • Despite strong results, stock fell 4.64% to $150.73, reflecting potential investor concerns or broader market influences
  • Full-year guidance: revenue $9.425-9.575B, organic growth 6-8%, adjusted EPS $6.20-6.30
  • Key product lines like Simparica and OA pain monoclonal antibodies showed significant growth
  • Executives highlighted industry resilience but noted regulatory and competitive challenges ahead
Last Updated: 06/05/2025, 15:08
Read Full Transcript

Compare ZTS to Peers and Sector

Metrics to compare
ZTS
Peers
Sector
Relationship
P/E Ratio
26.7x−0.1x−0.5x
PEG Ratio
3.640.000.00
Price/Book
14.4x0.9x2.6x
Price / LTM Sales
7.2x0.8x3.2x
Upside (Analyst Target)
29.4%19.7%41.2%
Fair Value Upside
Unlock27.2%6.2%Unlock

Analyst Ratings

13 Buy
5 Hold
0 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 195.55
(+29.49% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.58%
Dividend Yield
1.32%
Industry Median 2.83%
Annualised payout
2.00
Paid quarterly
5-Years Growth
+21.02%
Growth Streak

Earnings

Latest Release
May 06, 2025
EPS / Forecast
1.48 / 1.41
Revenue / Forecast
2.22B / 2.20B
EPS Revisions
Last 90 days

ZTS Income Statement

People Also Watch

25.53
CNC
-4.95%
142.50
FI
+1.83%
45.03
BILL
-2.27%
214.04
LULU
-1.18%
84.67
QRVO
+0.42%

FAQ

What Stock Exchange Does Zoetis Inc Trade On?

Zoetis Inc is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Zoetis Inc?

The stock symbol for Zoetis Inc is "ZTS."

What Is the Zoetis Inc Market Cap?

As of today, Zoetis Inc market cap is 67.11B.

What Is Zoetis Inc's Earnings Per Share (TTM)?

The Zoetis Inc EPS (TTM) is 5.58.

When Is the Next Zoetis Inc Earnings Date?

Zoetis Inc will release its next earnings report on 04 Aug 2025.

From a Technical Analysis Perspective, Is ZTS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Zoetis Inc Stock Split?

Zoetis Inc has split 0 times.

How Many Employees Does Zoetis Inc Have?

Zoetis Inc has 13800 employees.

What is the current trading status of Zoetis Inc (ZTS)?

As of 29 Jul 2025, Zoetis Inc (ZTS) is trading at a price of 151.02, with a previous close of 150.75. The stock has fluctuated within a day range of 148.54 to 151.04, while its 52-week range spans from 139.70 to 200.33.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.